keyword
MENU ▼
Read by QxMD icon Read
search

hiv long acting injectable

keyword
https://www.readbyqxmd.com/read/28527854/barriers-to-initiation-of-extended-release-naltrexone-among-hiv-infected-adults-with-alcohol-use-disorders
#1
Hélène Chokron Garneau, Alexandra Venegas, Richard Rawson, Lara A Ray, Suzette Glasner
Alcohol consumption is a major risk factor for the acquisition of HIV/AIDS and is associated with greater disease burden and mortality among those who become HIV-infected. Of the extant pharmacological treatments for alcohol use disorders, naltrexone is recognized as one of the most efficacious, producing robust reductions in alcohol craving and use. Given that treatment with oral naltrexone has been limited by problems with adherence, which are particularly prevalent among individuals with multiple chronic, co-occurring conditions, long-acting formulations may be a promising approach for HIV-infected substance users...
May 11, 2017: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/28498144/the-impact-of-preexposure-prophylaxis-among-men-who-have-sex-with-men-an-individual-based-model
#2
Parastu Kasaie, Jeff Pennington, Maunank S Shah, Stephen A Berry, Danielle German, Colin P Flynn, Chris Beyrer, David W Dowdy
OBJECTIVES: Preexposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation. DESIGN: We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage, and use of antiretroviral therapy...
June 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28368868/universal-antiretroviral-regimens-thinking-beyond-one-pill-once-a-day
#3
Jeffrey M Jacobson, Charles Flexner
PURPOSE OF REVIEW: Poor adherence to oral antiretroviral treatment in a subpopulation of persons with HIV-1 infection interferes with the potential success of the drug regimens in treating the infection. Here, we review long-acting antiretroviral strategies currently in clinical development that could prove useful for the treatment of HIV-1 infection in individuals not succeeding with short-acting oral regimens. RECENT FINDINGS: Pharmaceutical nanotechnology has succeeded in creating two novel long-acting injectable antiretroviral compounds, carbotegravir and rilpivirine, which have completed early clinical trials demonstrating the safety, tolerability and prolonged antiretroviral activity...
March 31, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28356041/recent-advances-in-antiretroviral-agents-potent-integrase-inhibitors
#4
Mina Psichogiou, Garyphalia Poulakou, Dimitrios Basoulis, Dimitrios Paraskevis, Antonios Markogiannakis, George L Daikos
Integrase strand transfer inhibitors (INSTIs) belong to a novel class of antiretroviral agents that have emerged as the new first-line treatments. Three such compounds are currently available, raltegravir, elvitegravir, dolutegravir and two more under development, bictegravir and cabotegravir. These compounds share the same mode of action but exhibit different pharmacokinetic/ pharmacodynamic properties, and drug-drug interactions. A series of studies in the past decade have established their efficacy compared to previous regimens, both in treatment-naïve and experienced patients...
March 29, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28291047/the-impact-of-pre-exposure-prophylaxis-among-men-who-have-sex-with-men-an-individual-based-model
#5
Parastu Kasaie, Jeff Pennington, Maunank S Shah, Stephen A Berry, Danielle German, Colin P Flynn, Chris Beyrer, David W Dowdy
OBJECTIVES: Pre-exposure prophylaxis (PrEP) is recommended for preventing HIV infection among individuals at high risk, including men who have sex with men (MSM). Although its individual-level efficacy is proven, questions remain regarding population-level impact of PrEP implementation. DESIGN: We developed an agent-based simulation of HIV transmission among MSM, accounting for demographics, sexual contact network, HIV disease stage and use of antiretroviral therapy...
March 10, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28285153/contraceptive-method-and-self-reported-hiv-status-among-women-in-malawi
#6
Jamie E Luster, Abigail Norris Turner, Duna Alkhalaileh, Maria F Gallo
OBJECTIVES: We aimed to describe contraceptive methods used by women in Malawi and determine whether contraceptive use differed by self-reported HIV status. Effective contraception is a primary method of preventing mother-to-child transmission of HIV. STUDY DESIGN: Analysis is based on 12,658 nonpregnant, sexually debuted women ages 15-49 years in the 2010 Malawi Demographic and Health Survey. Analysis was restricted to respondents with contraceptive need (i.e., fecund and did not want a child in the next 12 months) who reported their last HIV test result...
March 8, 2017: Contraception
https://www.readbyqxmd.com/read/28121666/tenofovir-alafenamide-and-elvitegravir-loaded-nanoparticles-for-long-acting-prevention-of-hiv-1-vaginal-transmission
#7
Subhra Mandal, Pavan K Prathipati, Guobin Kang, You Zhou, Zhe Yuan, Wenjin Fan, Qingsheng Li, Christopher J Destache
OBJECTIVE: This report presents tenofovir (TFV) alafenamide (TAF) and elvitegravir (EVG) fabricated into nanoparticles for subcutaneous delivery as prevention strategy. DESIGN: Prospective prevention study in humanized bone marrow-liver-thymus (hu-BLT) mice. METHODS: Using an oil-in-water emulsion solvent evaporation technique, TAF + EVG drugs were entrapped together into nanoparticles containing poly(lactic-co-glycolic acid). In-vitro prophylaxis studies (90% inhibition concentration) compared nanoparticles with drugs in solution...
February 20, 2017: AIDS
https://www.readbyqxmd.com/read/28011389/extended-release-naltrexone-for-pre-release-prisoners-a-randomized-trial-of-medical-mobile-treatment
#8
Michael S Gordon, Frank J Vocci, Terrence T Fitzgerald, Kevin E O'Grady, Charles P O'Brien
BACKGROUND: Extended-release naltrexone (XR-NTX), is an effective treatment for opioid use disorder but is rarely initiated in US prisons or with criminal justice populations. Mobile treatment for chronic diseases has been implemented in a variety of settings. Mobile treatment may provide an opportunity to expand outreach to parolees to surmount barriers to traditional clinic treatment. METHODS: Male and female prisoners (240) with pre-incarceration histories of opioid use disorder who are within one month of release from prison will be enrolled in this randomized clinical trial...
February 2017: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27799824/profile-of-cabotegravir-and-its-potential-in-the-treatment-and-prevention-of-hiv-1-infection-evidence-to-date
#9
REVIEW
Thomas Whitfield, Adele Torkington, Clare van Halsema
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience. Cabotegravir is an integrase strand transfer inhibitor and an analog of dolutegravir. Unlike dolutegravir, cabotegravir has a long half-life and can be formulated into a long-acting nanosuspension for parenteral administration. Initial pharmokinetic studies in humans have demonstrated adequate drug levels with intramuscular (IM) administration at 4 weekly and 8 weekly intervals, with few interactions with commonly used concomitant medications...
2016: HIV/AIDS: Research and Palliative Care
https://www.readbyqxmd.com/read/27771050/progress-in-formulation-based-approaches-for-antiretrovirals
#10
Ameya R Kirtane, Robert Langer, Giovanni Traverso
The human immunodeficiency virus has infected millions of people and the epidemic continues to grow rapidly in some parts of the world. Antiretroviral (ARV) therapy has provided improved treatment and prolonged the life expectancy of patients. Moreover, there is growing interest in using ARVs to protect against new infections. Hence, ARVs have emerged as our primary strategy in combating the virus. Unfortunately, several challenges limit the optimal performance of these drugs. First, ARVs often require life-long use and complex dosing regimens...
October 19, 2016: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27770215/preferences-for-long-acting-pre-exposure-prophylaxis-prep-daily-oral-prep-or-condoms-for-hiv-prevention-among-u-s-men-who-have-sex-with-men
#11
George J Greene, Greg Swann, Angela J Fought, Alex Carballo-Diéguez, Thomas J Hope, Patrick F Kiser, Brian Mustanski, Richard T D'Aquila
HIV prevention method preferences were evaluated among 512 U.S. men who have sex with men (MSM; median age: 22 years). Approximately 90 % consistently preferred one option across pairwise comparisons of condoms, daily oral pre-exposure prophylaxis (PrEP), and long-acting PrEP delivered via either an injectable or one of two types of PrEP implants differing in visibility. Condoms were most frequently preferred (33.8 %), followed by non-visible implants (21.5 %), and oral PrEP (17.0 %); HIV risk was reported by more choosing implants...
May 2017: AIDS and Behavior
https://www.readbyqxmd.com/read/27703992/deciphering-the-effects-of-injectable-pre-exposure-prophylaxis-for-combination-human-immunodeficiency-virus-prevention
#12
Robert L Glaubius, Urvi M Parikh, Greg Hood, Kerri J Penrose, Eran Bendavid, John W Mellors, Ume L Abbas
Background.  A long-acting injectable formulation of rilpivirine (RPV), under investigation as antiretroviral pre-exposure prophylaxis (PrEP), may facilitate PrEP adherence. In contrast, cross-resistance between RPV and nonnucleoside reverse-transcriptase inhibitors comprising first-line antiretroviral therapy (ART) could promote human immunodeficiency virus (HIV) drug resistance and reduce PrEP's effectiveness. Methods.  We use novel mathematical modeling of different RPV PrEP scale-up strategies in KwaZulu-Natal, South Africa, to investigate their effects on HIV prevention and drug resistance, compared with a reference scenario without PrEP...
September 2016: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/27658864/long-acting-rilpivirine-as-potential-pre-exposure-prophylaxis-for-hiv-1-prevention-the-mwri-01-study-an-open-label-phase-1-compartmental-pharmacokinetic-and-pharmacodynamic-assessment
#13
Ian McGowan, Charlene S Dezzutti, Aaron Siegel, Jarret Engstrom, Alexiy Nikiforov, Kathryn Duffill, Cory Shetler, Nicola Richardson-Harman, Kaleab Abebe, David Back, Laura Else, Deidre Egan, Saye Khoo, James E Egan, Ronald Stall, Peter E Williams, Khaleel K Rehman, Amy Adler, Rhonda M Brand, Beatrice Chen, Sharon Achilles, Ross D Cranston
BACKGROUND: Long-acting injectable antiretroviral agents are being developed for HIV-1 prevention. The MWRI-01 study was done to characterise the safety, acceptability, and pharmacokinetic and pharmacodynamic profile of long-acting rilpivirine. METHODS: We did a phase 1 open-label study at the University of Pittsburgh. We enrolled healthy individuals (aged 18-45 years) who were seronegative for HIV-1. Participants were assigned alternately one intramuscular dose of either 1200 mg or 600 mg long-acting rilpivirine, beginning with the 1200 mg dose...
December 2016: Lancet HIV
https://www.readbyqxmd.com/read/27444753/antiretroviral-pre-exposure-prophylaxis-preferences-among-men-who-have-sex-with-men-in-vietnam-results-from-a-nationwide-cross-sectional-survey
#14
Catherine E Oldenburg, Bao Le, Hoang Thi Huyen, Dinh Duc Thien, Nguyen Hoang Quan, Katie B Biello, Amy Nunn, Philip A Chan, Kenneth H Mayer, Matthew J Mimiaga, Donn Colby
Background: The HIV/AIDS epidemic in Vietnam is concentrated in subgroups of the population, including men who have sex with men (MSM). Pre-exposure prophylaxis (PrEP) is a viable strategy for HIV prevention, but knowledge about and preferences for PrEP delivery among Vietnamese MSM are not well understood. Methods: In 2015, an online survey was conducted with recruitment via social networking websites for MSM and peer recruitment. A description of daily oral, long-acting injectable, and rectal microbicide formulations of PrEP was provided to participants...
July 22, 2016: Sexual Health
https://www.readbyqxmd.com/read/27398863/croi-2016-advances-in-antiretroviral-therapy
#15
REVIEW
Barbara S Taylor, Susan A Olender, Hong-Van Tieu, Timothy J Wilkin
The 2016 Conference on Retroviruses and Opportunistic Infections highlighted exciting advances in antiretroviral therapy, including important data on investigational antiretroviral drugs and clinical trials. Clinical trials demonstrated benefits from a long-acting injectable coformulation given as maintenance therapy, examined intravenous and subcutaneous administration of a monoclonal antibody directed at the CD4 binding site of HIV-1, and provided novel data on tenofovir alafenamide. Several studies focused on the role of HIV drug resistance, including the significance of minority variants, transmitted drug resistance, use of resistance testing, and drug class-related resistance...
May 2016: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/27398859/croi-2016-hot-spots-in-hiv-infection-and-advances-in-hiv-prevention
#16
REVIEW
Susan P Buchbinder, Albert Y Liu
The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted hot spots in HIV infection. Men who have sex with men (MSM), transgender populations, people who inject drugs, fisherfolk, migrants, adolescents, and older adults are heavily impacted in a number of regions. Stigma contributes to risk behaviors and HIV acquisition across populations. HIV testing is a crucial first step in the HIV care continuum, and several large community-based surveys are underway in Africa to increase HIV testing, linkage to care, and uptake of antiretroviral treatment...
May 2016: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/27365203/maximising-hiv-prevention-by-balancing-the-opportunities-of-today-with-the-promises-of-tomorrow-a-modelling-study
#17
Jennifer A Smith, Sarah-Jane Anderson, Kate L Harris, Jessica B McGillen, Edward Lee, Geoff P Garnett, Timothy B Hallett
BACKGROUND: Many ways of preventing HIV infection have been proposed and more are being developed. We sought to construct a strategic approach to HIV prevention that would use limited resources to achieve the greatest possible prevention impact through the use of interventions available today and in the coming years. METHODS: We developed a deterministic compartmental model of heterosexual HIV transmission in South Africa and formed assumptions about the costs and effects of a range of interventions, encompassing the further scale-up of existing interventions (promoting condom use, male circumcision, early antiretroviral therapy [ART] initiation for all [including increased HIV testing and counselling activities], and oral pre-exposure prophylaxis [PrEP]), the introduction of new interventions in the medium term (offering intravaginal rings, long-acting injectable antiretroviral drugs) and long term (vaccine, broadly neutralising antibodies [bNAbs])...
July 2016: Lancet HIV
https://www.readbyqxmd.com/read/27354071/preferences-for-arv-based-hiv-prevention-methods-among-men-and-women-adolescent-girls-and-female-sex-workers-in-gauteng-province-south-africa-a-protocol-for-a-discrete-choice-experiment
#18
Matthew Quaife, Robyn Eakle, Maria Cabrera, Peter Vickerman, Motlalepule Tsepe, Fiona Cianci, Sinead Delany-Moretlwe, Fern Terris-Prestholt
INTRODUCTION: For the past few decades, condoms have been the main method of HIV prevention. Recent advances in antiretroviral (ARV)-based prevention products have substantially changed the prevention landscape, yet little is known about how popular these products will be among potential users, or whether new methods might be used in conjunction with, or instead of, condoms. This study will use a discrete choice experiment (DCE) to (1) explore potential users' preferences regarding HIV prevention products, (2) quantify the importance of product attributes and (3) predict the uptake of products to inform estimates of their potential impact on the HIV epidemic in South Africa...
2016: BMJ Open
https://www.readbyqxmd.com/read/27193745/cost-effectiveness-of-injectable-preexposure-prophylaxis-for-hiv-prevention-in-south-africa
#19
Robert L Glaubius, Greg Hood, Kerri J Penrose, Urvi M Parikh, John W Mellors, Eran Bendavid, Ume L Abbas
BACKGROUND: Long-acting injectable antiretrovirals such as rilpivirine (RPV) could promote adherence to preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) prevention. However, the cost-effectiveness of injectable PrEP is unclear. METHODS: We constructed a dynamic model of the heterosexual HIV epidemic in KwaZulu-Natal, South Africa, and analyzed scenarios of RPV PrEP scale-up for combination HIV prevention in comparison with a reference scenario without PrEP...
August 15, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27154460/saquinavir-loaded-acetalated-dextran-microconfetti-a-long-acting-protease-inhibitor-injectable
#20
Michael A Collier, Matthew D Gallovic, Eric M Bachelder, Craig D Sykes, Angela Kashuba, Kristy M Ainslie
PURPOSE: Since the adoption of highly active antiretroviral therapy, HIV disease progression has slowed across the world; however, patients are often required to take multiple medications daily of poorly bioavailable drugs via the oral route, leading to gastrointestinal irritation. Recently, long acting antiretroviral injectables that deliver drug for months at a time have moved into late phase clinical trials. Unfortunately, these solid phase crystal formulations have inherent drawbacks in potential dose dumping and a greater likelihood for burst release of drug compared to polymeric formulations...
August 2016: Pharmaceutical Research
keyword
keyword
114592
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"